

CITATION REPORT

List of articles citing

Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial

DOI: 10.1111/j.1745-7262.2007.00233.x
Asian Journal of Andrology, 2007, 9, 134-41.

Source: <https://exaly.com/paper-pdf/42920056/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
38	Chronic sildenafil in men with diabetes and erectile dysfunction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007 , 3, 451-64	5.5	24
37	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. <i>Aging Health</i> , 2007 , 3, 527-542		1
36	The Refill Rate and Reasons for Abandonment of Phosphodiesterase5 Inhibitors in Erectile Dysfunction Patients. <i>Korean Journal of Urology</i> , 2007 , 48, 646		1
35	Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence. <i>BJU International</i> , 2008 , 101, 1129-34	5.6	10
34	Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. <i>Diabetic Medicine</i> , 2008 , 25, 37-44	3.5	101
33	Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. <i>European Urology</i> , 2008 , 54, 213-20	10.2	41
32	Endothelial effects of drugs designed to treat erectile dysfunction. <i>Current Pharmaceutical Design</i> , 2008 , 14, 3768-78	3.3	24
31	A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. <i>BJU International</i> , 2010 , 105, 1634-9	5.6	26
30	Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. <i>Annals of Internal Medicine</i> , 2009 , 151, 639-49	8	58
29	Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , 2009 , 151, 650-61	8	137
28	Can we cure erectile dysfunction?. <i>European Urology</i> , 2010 , 58, 249-50	10.2	6
27	Endothelial dysfunction and erectile dysfunction in the aging man. <i>International Journal of Urology</i> , 2010 , 17, 38-47	2.3	91
26	Men with mild erectile dysfunction benefit from sildenafil treatment. <i>Journal of Sexual Medicine</i> , 2010 , 7, 3725-35	1.1	15
25	A cure, or return to a previous sexual state? Developments in the concept of cure in sexology. <i>Sexologies</i> , 2011 , 20, 3-7	0.5	
24	Guérir ou retrouver un État sexuel antérieur? Évolution du concept de guérison en sexologie. <i>Sexologies</i> , 2011 , 20, 38-41	0.5	
23	Do men with mild erectile dysfunction have the same risk factors as the general erectile dysfunction clinical trial population?. <i>BJU International</i> , 2011 , 107, 956-60	5.6	21
22	Chronic vardenafil treatment improves erectile function via structural maintenance of penile corpora cavernosa in rats with acute arteriogenic erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2011 , 8, 705-11	1.1	19

21	Poly(ADP-ribose) polymerase inhibition improves erectile function by activation of nitric oxide/cyclic guanosine monophosphate pathway in diabetic rats. <i>Journal of Sexual Medicine</i> , 2012 , 9, 1319-27	1.1	8
20	Effects of chronic vardenafil treatment persist after end of treatment in rats with acute arteriogenic erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2012 , 9, 1782-8	1.1	10
19	Rehabilitation of the cavernous smooth muscle in patients with organic erectile dysfunction. <i>Andrologia</i> , 2012 , 44, 125-9	2.4	1
18	VEGF genetic polymorphisms affect the responsiveness to sildenafil in clinical and postoperative erectile dysfunction. <i>Pharmacogenomics Journal</i> , 2013 , 13, 437-42	3.5	14
17	Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. <i>American Journal of Medicine</i> , 2013 , 126, 192-9	2.4	25
16	Should men with mild erectile dysfunction be closely evaluated for cardiovascular diseases in the Korean population?. <i>Aging Male</i> , 2014 , 17, 81-6	2.1	3
15	Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions. <i>Experimental Neurology</i> , 2014 , 251, 58-71	5.7	39
14	Pharmacogenetics of erectile dysfunction: navigating into uncharted waters. <i>Pharmacogenomics</i> , 2014 , 15, 1519-38	2.6	20
13	Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction. <i>Asian Journal of Andrology</i> , 2015 , 17, 143-8	2.8	6
12	Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. <i>European Journal of Endocrinology</i> , 2015 , 172, R103-114	6.5	66
11	Association Between Dosage Frequency and the Treatment Outcomes of Sildenafil in Young and Middle-aged Men With Erectile Dysfunction: A Chinese, Multicenter, Observational Study. <i>Urology</i> , 2015 , 86, 62-7	1.6	2
10	Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. <i>International Journal of Impotence Research</i> , 2015 , 27, 33-7	2.3	9
9	A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2016 , 13, 1263-9	1.1	2
8	[Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities]. <i>Revista Internacional De Andrología</i> , 2018 , 16, 28-33	0.6	
7	Mechanisms Involved in the Remyelinating Effect of Sildenafil. <i>Journal of NeuroImmune Pharmacology</i> , 2018 , 13, 6-23	6.9	7
6	Effect of treatment with testosterone on endothelial function in hypogonadal men: a systematic review and meta-analysis. <i>International Journal of Impotence Research</i> , 2020 , 32, 379-386	2.3	13
5	Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. <i>Asian Journal of Andrology</i> , 2016 , 18, 723-31	2.8	8
4	Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects. <i>International Neurourology Journal</i> , 2010 , 14, 7-12	2.6	5

- 3 A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With β Blockers and β Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction. *International Neurourology Journal*, **2015**, 19, 237-45 2.6 5
- 2 Postoperative Management. **2007**, 179-195
- 1 The flow index provides a comprehensive assessment of erectile dysfunction by combining blood flow velocity and vascular diameter. **2022**, 12, 0